Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripher...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yusuke Daido, Hiroyuki Sugiura, Tatsunori Ishikawa, Taiga Kuroi, Sachiyo Okamoto, Naho Nomura, Taro Masunari, Nobuo Sezaki, Yasuhito Nannya, Seishi Ogawa, Mitsune Tanimoto
Format:	Artigo
Jezik:	Inglês
Izdano:	Karger Publishers 2023-09-01
Serija:	Case Reports in Oncology
Teme:	acute myeloid leukemia venetoclax-azacitidine ptcy-haplo-pbsct idh2 mutation
Online dostop:	https://beta.karger.com/Article/FullText/533749
Oznake:	Označite Brez oznak, prvi označite!